Boehringer Ingelheim (Canada) Ltd./Ltée

Boehringer Ingelheim (Canada) Ltd./Ltée is the Canadian subsidiary of Boehringer Ingelheim, a global, research-driven biopharmaceutical company. Founded in 1885 and remaining family-owned, the company's mission is to improve human and animal health by developing breakthrough therapies and life-enhancing improvements, with a strong focus on areas of high unmet medical need. Its Canadian headquarters are located in Burlington, Ontario.

The company operates across three main business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In Human Pharma, Boehringer Ingelheim focuses on therapeutic research in cardiovascular, renal and metabolic diseases (CRM), oncology, respiratory diseases, immunology, mental health, and retinal health. Its Animal Health portfolio includes parasiticides, therapeutics, and vaccines for companion animals, equine, and livestock.

Boehringer Ingelheim has demonstrated strong pipeline acceleration, with significant investments in Research & Development. Recent news highlights include advancements in treatments for obesity and type 2 diabetes, ongoing oncology research, and strategic partnerships in veterinary care and lung cancer diagnostics. As a privately held entity, the company emphasizes a long-term strategic vision over short-term market pressures, distinguishing itself as one of the world's largest pharmaceutical companies and the largest private one.